These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
329 related articles for article (PubMed ID: 23705859)
1. Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the Sister Study cohort. Godfrey AC; Xu Z; Weinberg CR; Getts RC; Wade PA; DeRoo LA; Sandler DP; Taylor JA Breast Cancer Res; 2013 May; 15(3):R42. PubMed ID: 23705859 [TBL] [Abstract][Full Text] [Related]
2. Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: a case control study. Kodahl AR; Lyng MB; Binder H; Cold S; Gravgaard K; Knoop AS; Ditzel HJ Mol Oncol; 2014 Jul; 8(5):874-83. PubMed ID: 24694649 [TBL] [Abstract][Full Text] [Related]
3. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. van Schooneveld E; Wouters MC; Van der Auwera I; Peeters DJ; Wildiers H; Van Dam PA; Vergote I; Vermeulen PB; Dirix LY; Van Laere SJ Breast Cancer Res; 2012 Feb; 14(1):R34. PubMed ID: 22353773 [TBL] [Abstract][Full Text] [Related]
4. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer. McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016 [TBL] [Abstract][Full Text] [Related]
5. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. Schrauder MG; Strick R; Schulz-Wendtland R; Strissel PL; Kahmann L; Loehberg CR; Lux MP; Jud SM; Hartmann A; Hein A; Bayer CM; Bani MR; Richter S; Adamietz BR; Wenkel E; Rauh C; Beckmann MW; Fasching PA PLoS One; 2012; 7(1):e29770. PubMed ID: 22242178 [TBL] [Abstract][Full Text] [Related]
6. Expression of miR-18a and miR-210 in Normal Breast Tissue as Candidate Biomarkers of Breast Cancer Risk. Shidfar A; Costa FF; Scholtens D; Bischof JM; Sullivan ME; Ivancic DZ; Vanin EF; Soares MB; Wang J; Khan SA Cancer Prev Res (Phila); 2017 Jan; 10(1):89-97. PubMed ID: 27789587 [TBL] [Abstract][Full Text] [Related]
7. MiRNA-513a-5p inhibits progesterone receptor expression and constitutes a risk factor for breast cancer: the hOrmone and Diet in the ETiology of breast cancer prospective study. Muti P; Donzelli S; Sacconi A; Hossain A; Ganci F; Frixa T; Sieri S; Krogh V; Berrino F; Biagioni F; Strano S; Beyene J; Yarden Y; Blandino G Carcinogenesis; 2018 Feb; 39(2):98-108. PubMed ID: 29126102 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-484 is more highly expressed in serum of early breast cancer patients compared to healthy volunteers. Zearo S; Kim E; Zhu Y; Zhao JT; Sidhu SB; Robinson BG; Soon PSh BMC Cancer; 2014 Mar; 14():200. PubMed ID: 24641801 [TBL] [Abstract][Full Text] [Related]
10. Identification of circulating microRNA signatures for breast cancer detection. Chan M; Liaw CS; Ji SM; Tan HH; Wong CY; Thike AA; Tan PH; Ho GH; Lee AS Clin Cancer Res; 2013 Aug; 19(16):4477-87. PubMed ID: 23797906 [TBL] [Abstract][Full Text] [Related]
11. Differential expression of the miR-17-92 cluster and miR-17 family in breast cancer according to tumor type; results from the Norwegian Women and Cancer (NOWAC) study. Moi L; Braaten T; Al-Shibli K; Lund E; Busund LR J Transl Med; 2019 Oct; 17(1):334. PubMed ID: 31581940 [TBL] [Abstract][Full Text] [Related]
12. Identification of microRNA biomarkers in the blood of breast cancer patients based on microRNA profiling. Zhang K; Wang YW; Wang YY; Song Y; Zhu J; Si PC; Ma R Gene; 2017 Jul; 619():10-20. PubMed ID: 28359916 [TBL] [Abstract][Full Text] [Related]
13. Identification and validation of miRNAs as endogenous controls for RQ-PCR in blood specimens for breast cancer studies. McDermott AM; Kerin MJ; Miller N PLoS One; 2013; 8(12):e83718. PubMed ID: 24391813 [TBL] [Abstract][Full Text] [Related]
14. Next-generation sequencing of microRNAs for breast cancer detection. Wu Q; Lu Z; Li H; Lu J; Guo L; Ge Q J Biomed Biotechnol; 2011; 2011():597145. PubMed ID: 21716661 [TBL] [Abstract][Full Text] [Related]
15. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Hafez MM; Hassan ZK; Zekri AR; Gaber AA; Al Rejaie SS; Sayed-Ahmed MM; Al Shabanah O Asian Pac J Cancer Prev; 2012; 13(2):591-8. PubMed ID: 22524830 [TBL] [Abstract][Full Text] [Related]
16. MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Lowery AJ; Miller N; Devaney A; McNeill RE; Davoren PA; Lemetre C; Benes V; Schmidt S; Blake J; Ball G; Kerin MJ Breast Cancer Res; 2009; 11(3):R27. PubMed ID: 19432961 [TBL] [Abstract][Full Text] [Related]
17. Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer. McAnena P; Tanriverdi K; Curran C; Gilligan K; Freedman JE; Brown JAL; Kerin MJ BMC Cancer; 2019 May; 19(1):436. PubMed ID: 31077182 [TBL] [Abstract][Full Text] [Related]
18. Identification of serum miR-1915-3p and miR-455-3p as biomarkers for breast cancer. Guo J; Liu C; Wang W; Liu Y; He H; Chen C; Xiang R; Luo Y PLoS One; 2018; 13(7):e0200716. PubMed ID: 30048472 [TBL] [Abstract][Full Text] [Related]
19. Differentially expressed microRNAs in postpartum breast cancer in Hispanic women. Muñoz-Rodríguez JL; Vrba L; Futscher BW; Hu C; Komenaka IK; Meza-Montenegro MM; Gutierrez-Millan LE; Daneri-Navarro A; Thompson PA; Martinez ME PLoS One; 2015; 10(4):e0124340. PubMed ID: 25875827 [TBL] [Abstract][Full Text] [Related]
20. Expression differences of circulating microRNAs in metastatic castration resistant prostate cancer and low-risk, localized prostate cancer. Nguyen HC; Xie W; Yang M; Hsieh CL; Drouin S; Lee GS; Kantoff PW Prostate; 2013 Mar; 73(4):346-54. PubMed ID: 22887127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]